Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation    DNDN   US24823Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/25/2014 08/26/2014 08/27/2014 08/28/2014 08/29/2014 Date
1.34(c) 1.4(c) 1.37(c) 1.36(c) 1.359 Last
2 015 776 2 482 322 2 046 278 951 204 475 360 Volume
+1.52% +4.48% -2.14% -0.73% -0.07% Change
More quotes
Company
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular... 
Surperformance© rating of Dendreon Corporation
Trading Rating : Investor Rating :
More about the company
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | DNDN | US24823Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 303 M
EBIT 2014 -66,1 M
Net income 2014 -124 M
Debt 2014 411 M
Yield 2014 -
Sales 2015 348 M
EBIT 2015 -35,8 M
Net income 2015 -90,1 M
Debt 2015 376 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 2,08x
EV / Sales 2015 1,71x
Capitalization 218 M
More Financials
Latest news on DENDREON CORPORATION
08/12 DENDREON : sinks after drugmaker warns of debt woes
08/11 DENDREON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
08/06 Dendreon Names W. Thomas Amick President and Chief Executive Officer
08/06 DENDREON : Elects W. Thomas Amick as President and CEO
08/04 DENDREON : Taps W. Thomas Amick President
07/31 DENDREON : Names W. Thomas Amick President and Chief Executive Officer
07/30 DENDREON : Change in Directors or Principal Officers, Financial Statements and E..
07/30 DENDREON : Names W. Thomas Amick President and Chief Executive Officer
06/18 DENDREON : Termination of a Material Definitive Agreement (form 8-K)
06/09 DENDREON : Change in Directors or Principal Officers, Financial Statements and E..
06/09 DENDREON : Announces Leadership Transition
05/28 DENDREON : Treatment with PROVENGE® sipuleucel-T Induces Antigen Spread Associat..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
Dendreon Corporation : Income Statement Evolution
More Financials
EPS Revisions
Dendreon Corporation : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF